Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. Epilepsy is the
fourth most common neurological disorder and affects people of all ages. The patients are
reported to loss or disturbance of consciousness and movements along with sensory or
psychiatric disturbances. Increasing prevalence of the epilepsy, rising per capita healthcare
expenditure and increasing R&D for the therapeutic procedures of the disease drives the
market growth during the forecast period, 2017-2022. According to the World Health
Organization in 2017, approximately 50 million people across the globe have epilepsy,
making it one of the most common neurological diseases globally. Moreover, it was
estimated that nearly 80% of the people with epilepsy live in low- and middle-income
countries. Additionally, approval of several late-stage pipeline molecules, advancements in
drugs modification and favourable government initiative fuels the market growth. However,
side effects related to the therapeutic drugs, increasing generic competition and patent
expirations are some of the restrains that for the growth during the forecast period.
The Global Anti-Epilepsy Drugs Market is growing with the sound pace. According to a
recent study report published by the Market Research Future, The global anti-epilepsy drugs
market is booming and expected to gain prominence over the forecast period growing
rapidly .The market is forecasted to demonstrate a sound growth by 2022, surpassing its
previous growth records in terms of value with a striking CAGR during the anticipated period
(2017 – 2022).
Global Anti-Epilepsy Drugs Market - Competitive Analysis
Characterized by the presence of several well-established and small players, the global anti-
epilepsy drugs market appears to be highly competitive and fragmented. International
players who are increasingly expanding their footprint in the developing economy, making it
difficult for regional vendors to compete with them, especially in terms of features such as
product differentiation, product portfolios, quality, and pricing. The market is witnessing
intensified competition which is expected to get more intensified further during the forecast
period. The intense competition prevalent in the market dictates the consolidation among
marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and
product launch in order to gain competitive advantage in this market and to maintain their
market position.
Pfizer Inc. is one of the major players of the global anti-epilepsy drugs market and is
headquartered in the U.S. In 2015, the company’s total revenue was about USD 48,851
million and it reached USD 52,824 million in 2016. Such a significant increase in the global
sales, enabled the company to invest a huge percentage of their sales into the research and
development. In 2016, the company spent 14.9% of its total revenue into the R&D enabling
it to improve its product portfolio and launch new product, strengthening its position in the
market.
In October 2016, Abbott has collaborated with Celgene and Agios for diagnostic
identification of IDH mutations. Celgene has done an agreement with Abbott to develop and
commercialize the diagnostic tests.
In November 2016, Novartis acquired Selexys Pharmaceuticals Corporation, a company
specializing in development of therapeutics in certain hematologic and inflammatory
disorders.
In August 2017, Sanofi completed the acquisition of Protein Sciences, a vaccines
biotechnology company based in Meriden, Connecticut in the United States. This acquisition
was followed by the Federal Trade Commission approval, having met all the conditions
required for the closing of the transaction.
Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott, GlaxoSmithKline plc, Novartis
AG, Sanofi, Shire Pharmaceuticals Limited and Cephalon Inc., are some of the prominent
players at the forefront of competition in the Global Anti-epilepsy Drugs Market and are
profiled in MRFR Analysis.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/2345 .